EDITAS MEDICINE, INC. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
EDITAS MEDICINE, INC. (EDIT) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of $69.79 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2017-05-15
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was $69.79M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-12-31 was -$13.36M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-09-30 was -$17.04M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-06-30 was -$9.90M, a 148.41% decline year-over-year.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$49.93M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$5.40M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$8.65M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $69.79M 10-Q · filed 2017-05-15 | $56.43M derived: sum of 2 quarters · filed 2017-05-15 | $39.39M derived: sum of 3 quarters · filed 2017-05-15 | $29.49M derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-12-31 | -$13.36M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$30.40M derived: sum of 2 quarters · filed 2017-03-03 | -$40.30M derived: sum of 3 quarters · filed 2017-03-03 | -$49.93M 10-K · filed 2017-03-03 |
| 2016-09-30 | -$17.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$26.94M derived: sum of 2 quarters · filed 2016-11-09 | -$36.57M 10-Q · filed 2016-11-09 | -$44.54M derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-06-30 | -$9.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$19.53M 10-Q · filed 2016-08-10 | -$27.50M derived: sum of 3 quarters · filed 2017-05-15 | -$39.44M derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-03-31 | -$9.63M 10-Q · filed 2017-05-15 | -$17.60M derived: sum of 2 quarters · filed 2017-05-15 | -$29.54M derived: sum of 3 quarters · filed 2017-05-15 | -$9.09M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$19.91M derived: sum of 2 quarters · filed 2017-03-03 | $540.00K derived: sum of 3 quarters · filed 2017-03-03 | -$5.40M 10-K · filed 2017-03-03 |
| 2015-09-30 | -$11.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $8.51M derived: sum of 2 quarters · filed 2016-11-09 | $2.56M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $20.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $14.51M 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | -$5.94M 10-Q · filed 2016-05-13 | |||
| 2014-12-31 | -$8.65M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |